{"id":"W2995808512","doi":"10.1056/nejmoa1914609","title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1313,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Seattle Genetics","keywords":"Capecitabine; Trastuzumab; Metastatic breast cancer; Oncology; Medicine; Internal medicine; Breast cancer; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03135860786207033,"score_gpt":0.3704714722607771,"score_spread":0.3391128643987068,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}